Consolidated Financial Results for the First Three Months of the Fiscal Year Ending May 31, 2026 (Japan GAAP)

September 25, 2025

Company name:	Pharmarise Holdings Corporation	Listed on:	Tokyo Stock Exchange, Standard Market
Code number:	2796	URL	https://www.pharmarise.com/en/
Representative:	Masayuki Akiyama, President and Representative Director		
Inquiries:	Yutaka Numata, Director	Phone:	+81-3-3362-7130

Scheduled date to commence dividend payments: —
Preparation of supplementary material on financial results: None
Holding of financial results briefing: Yes (for analysts and institutional investors)

(Amounts of less than one million yen are rounded down.)

1. Consolidated financial results for the first three months of the fiscal year ending May 31, 2026 (from June 1, 2025 to August 31, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
August 31, 2025	16,753	10.0	152	188.5	115	399.1	(18)	–
August 31, 2024	15,231	13.1	52	(84.1)	23	(93.0)	(131)	–

(Note) Comprehensive income Three months ended August 31, 2025: -24 million yen [–%]
Three months ended August 31, 2024: -136 million yen [–%]

	Earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
August 31, 2025	(1.62)	–
August 31, 2024	(11.68)	–

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
August 31, 2025	30,171	6,637	21.2
May 31, 2025	31,924	6,918	20.9

(Reference) Equity As of August 31, 2025: 6,408 million yen As of May 31, 2025: 6,659 million yen

2. Cash dividends

	Dividend per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Annual
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended May 31, 2025	–	0.00	–	14.00	14.00
Fiscal year ending May 31, 2026	–				
Fiscal year ending May 31, 2026 (forecast)		0.00	–	14.00	14.00

(Note) Revision to the dividend forecast announced most recently: None

3. Consolidated earnings forecasts for the fiscal year ending May 31, 2026 (from June 1, 2025 to May 31, 2026)

(Percentages represent year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Six months	33,144	8.5	390	287.2	363	–	99	–	8.80
Full year	66,795	5.2	1,123	282.2	941	587.3	266	–	23.45

(Note) Revision to the financial results forecast announced most recently: None

* Notes
(1) Significant changes in the scope of consolidation during the period: No
New: — (company name)　　Exception: — (company name)

(2) Application of accounting procedures specific to preparation of the consolidated quarterly financial statements: Yes
Note: Please see “2. Consolidated Financial Statements and Notes on Important Matters, (3) Notes on quarterly consolidated financial statements” on page 11 of the Accompanying Materials for more details.

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i)	Changes in accounting policies due to the revision of accounting standards:	None
(ii)	Changes in accounting policies other than (i):	None
(iii)	Changes in accounting estimates:	None
(iv)	Retrospective restatement:	None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares):

As of August 31, 2025	12,060,381 shares	As of May 31, 2025	12,060,381 shares

(ii) Total number of treasury shares at the end of the period:

As of August 31, 2025	699,476 shares	As of May 31, 2025	699,476 shares

(iii) Average number of shares issued and outstanding in each period (cumulative from the beginning of the fiscal year):

Three months ended August 31, 2025	11,360,905 shares	Three months ended August 31, 2024	11,243,215 shares

* Review by certified public accountants or audit firms of the attached quarterly consolidated financial statements: No

* Explanation regarding appropriate use of business forecasts and other special instructions
The forward-looking statements such as the forecasts of financial results stated in this document are based on the information currently available to the Company and certain assumptions that the Company judges as rational. These statements are not guarantees of future performance. Actual results may differ materially, depending on a range of factors. For assumed conditions underlying the earnings forecast and cautionary statements in using the earnings forecast, please refer to “Explanation about the future outlook, including forecast for consolidated earnings” on page 6.

Accompanying Materials – Contents

1. Qualitative Information on Quarterly Financial Results for the Period under Review

(1) Explanation regarding operating results

During the first three months of the consolidated fiscal year under review (June 1, 2025 through August 31, 2025), the Japanese economic outlook remained uncertain, mainly due to the impact of U.S. trade policies, persistent inflation, and the volatile financial and capital markets. However, improvements in the employment and income environments and effects of various policies are expected to support gradual recovery of the economy.

In this environment, Pharmarise Holdings Corporation (the “Company”) and its consolidated subsidiaries (the “Group”) announced the new Medium-term Management Plan “Make a Leap 2027-Strengthen Foothold for a Further Leap Forward” (the “New Medium-term Management Plan”) on June 25, 2025. The Group will strengthen its foothold through early completion of the post-merger integration (PMI) of newly acquired companies and pharmacies and the enhancement of its functions as family pharmacists and pharmacies, and it will focus firmly on growth strategies centered on the Dispensing Pharmacy Business that will lead to a further leap forward.

Under the New Medium-term Management Plan, the Group has redefined its mission, vision and values, set long-term goals of becoming a community-centered dispensing pharmacy group that is chosen and trusted by patients and a dispensing pharmacy group finely attuned to the health maintenance, medical and nursing care needs of all, especially the elderly, and established task forces for the implementation of the following growth strategies.

Dispensing Pharmacy Business

(1) Strengthen pharmacists’ family pharmacist function

(2) Maintain patient-centered pharmacy operation

(3) Thoroughly implement initiatives to increase the number of prescriptions filled

Other

(4) Adopt a more sophisticated approach to M&A

(5) Rebuild existing businesses except for Dispensing Pharmacy Business

(6) Pursue sustainable corporate growth (sustainability)

The Company aims to achieve net sales of 70,000 million yen, operating profit of 1,600 million yen and an ROIC of 4.5% in FY28/5.

During the first three months of the consolidated fiscal year under review, net sales totaled 16,753 million yen (up 10.0% year on year), with operating profit of 152 million yen (up 188.5%) and ordinary profit of 115 million yen (up 399.1%). Loss attributable to owners of parent came to 18 million yen (compared to a loss attributable to owners of parent of 131 million yen a year ago).

The increase in net sales is mainly attributable to an increase in dispensing pharmacy sales associated with an increase in the number of pharmacies, which was a result of M&A activity in the Dispensing Pharmacy Business in the previous consolidated fiscal year.

On the profit front, operating profit and ordinary profit increased year on year and loss attributable to owners of parent decreased by 112 million yen. This mainly reflects improvements in the profitability of the Dispensing Pharmacy Business, an increase in profit attributed to the pharmacies that joined the Group as a result of the M&A activity, and a decrease in the ratio of selling, general and administrative expenses that was a result of the streamlining of headquarters operations.

Segment performance was as follows.

Dispensing Pharmacy Business

In the first three months of the fiscal year under review, sales for the Dispensing Pharmacy Business increased 14.0% year on year, to 14,151 million yen, and the segment profit increased 178.1%, to 235 million yen. The sales increase mainly reflected growth in the number of prescriptions filled, driven by an increase in the number of pharmacies as a result of M&A activity, including the transfer of business from Kanichi Shoten Corporation and its group companies in December 2024, as well as new pharmacy openings. The main factors for the increase of profit are an increase of profit at pharmacies that joined the Group as a result of M&A activity, as well as an increase in dispensing technical fees, including regional support structure premiums related to facility criteria that have been addressed since the previous consolidated fiscal year.

In the previous consolidated fiscal year, the Company actively pursued M&A in line with the “Develop business, primarily the dispensing business, to enhance revenue” strategy, which resulted in the growth in net sales. Following the acquisition of pharmacies, the Company took urgent steps to integrate the acquired pharmacies into the Group, which has led to the growth in profit.

In operating pharmacies, the Group has been advancing initiatives following the growth strategies laid out in the New Medium-term Management Plan. As initiatives to improve patient services, the Group has focused primarily on being able to reduce patient burden through shorter waiting times and other measures and ensuring that patients receive their medications even during distribution instability (guaranteed access to medication), which is a materiality KPI for sustainability management. Among the growth strategies, Café Nyamarise, which is being implemented as an initiative for maintaining patient-centered pharmacy operations, is steadily expanding the range of its activities. Café Nyamarise is a form of dementia café and was opened as a place where people can freely seek advice or exchange information not only about dementia and care-related matters but also about worries that are difficult to talk about. Café Nyamarise is to be expanded nationwide. This initiative became the first in the dispensing pharmacy industry to be selected as a

participant in the Orange Innovation Project(Note) promoted by the Ministry of Economy, Trade and Industry. As a result, collaborations with other companies will be possible, which will lead to new initiatives. The Group's dispensing pharmacies are expected to function as local healthcare strongholds.
At the end of the first three months of the consolidated fiscal year under review, the Group operated 392 dispensing pharmacies. Since the end of the previous fiscal year, one pharmacy has been added and ten have been closed. The decrease in the number of pharmacies was a result of the resolution to close unprofitable pharmacies which was passed in the previous fiscal year and implemented in the fiscal year under review. There were 76 health support pharmacies (unchanged from the end of the previous consolidated fiscal year). The number of the Group's pharmacies cooperating with local health care facilities was 91 (a decrease of three) while the number of the Group's pharmacies cooperating with specialized medical institutions was four (unchanged). The Group will continue striving to increase the number of each type of pharmacy.
(Note) Official website of the Orange Innovation Project of the Ministry of Economy, Trade and Industry: https://www.dementia-pr.com/

Drug/Convenience Store Business
In the first three months of the fiscal year under review, sales for the Drug/Convenience Store Business decreased 8.5% year on year, to 2,079 million yen, and the segment loss was 4 million yen (compared to a segment profit of 17 million yen a year ago). The main factor for the decrease in net sales is the closure of unprofitable stores in the previous fiscal year. The decrease of profit is attributable to the decrease of net sales, but it also reflects an increase in commission expenses which were a result of a change to the rate of the fees paid to headquarters in the convenience store section. The number of the Group's stores without any pharmacy section at the end of the first three months of the fiscal year under review decreased one from the end of the previous fiscal year to 42 (53 including 11 stores with pharmacy section).

Storage and Management of Medical Documents Business
In the first three months of the fiscal year under review, sales for the Storage and Management of Medical Documents Business increased 2.0% year on year, to 157 million yen, and the segment profit increased 111.9%, to 15 million yen. The increase in sales and profit chiefly reflects the successful reduction of expenses, including labor and commission expenses, in addition to steady sales related to the storage and disposal of medical documents.

Medical Mall Management Business
Sales for the Medical Mall Management Business increased 0.1% year on year, to 128 million yen, and the segment profit decreased 26.1%, to 23 million yen in the first three months of the fiscal year under review. While sales remained steady, profit declined due to an increase in personnel expenses, including a rise in base salaries, as well as expenses related to capital investments, including investments to replace medical equipment. As the Company is approaching the time for it to replace diagnostic and other medical equipment, it expects that depreciation expenses resulting from capital investments will continue to increase for the time being. However, the Company plans to maintain profitability by simultaneously revising administration fees, medical equipment usage fees, and rents charged to tenant medical institutions.

Other
In the first three months of the fiscal year under review, sales for the businesses in the Other segment decreased 7.8% year on year, to 235 million yen, and the segment loss was 35 million yen (compared to a segment loss of 7 million yen a year ago). The decrease in sales is mainly due to a temporary decrease in the number of contracts for projects in the paid placement and temporary help businesses. The decrease in profit reflects upfront expenses which were mainly a result of depreciation that is associated with the continued development of new products in the medical IT solutions business.

(2) Explanation regarding financial position

(Assets)

Assets at the end of the first three months of the fiscal year under review totaled 30,171 million yen, a decrease of 1,753 million yen from the end of the previous fiscal year. This was mainly attributable to a decrease of 2,786 million yen in cash and deposits from the end of the previous fiscal year, to 2,124 million yen, which was partly offset by an increase in merchandise and finished goods of 825 million yen from the end of the previous fiscal year, to 4,891 million yen.

(Liabilities)

Liabilities amounted to 23,533 million yen, a decrease of 1,472 million yen from the end of the previous fiscal year. This was primarily due to accounts payable - trade decreasing 327 million yen from the end of the previous fiscal year to 6,320 million yen, other (current liabilities) decreasing 671 million yen from the end of the previous fiscal year to 1,648 million yen, and long-term borrowings decreasing 593 million yen from the end of the previous fiscal year to 10,459 million yen.

(Net assets)

Net assets amounted to 6,637 million yen, a decrease of 280 million yen from the end of the previous fiscal year. The main factor was a decrease in the balance of retained earnings due to dividend payment.

(3) Explanation about the future outlook, including forecast for consolidated earnings

No changes have been made to the consolidated earnings forecasts for fiscal year ending May 31, 2026, which was announced in the summary of financial results as of June 25, 2025.

2. Consolidated Financial Statements and Notes on Important Matters

(1) Quarterly consolidated balance sheet

(Million yen)

	As of May 31, 2025	As of August 31, 2025
Assets		
Current assets		
Cash and deposits	4,911	2,124
Accounts receivable	738	802
Merchandise and finished goods	4,065	4,891
Raw materials and supplies	81	83
Accounts receivable - other	3,050	3,305
Other	398	461
Allowance for doubtful accounts	(7)	(6)
Total current assets	13,239	11,662
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	3,474	3,490
Land	2,919	2,985
Other, net	815	803
Total property, plant and equipment	7,209	7,279
Intangible assets		
Goodwill	6,800	6,604
Other	466	449
Total intangible assets	7,266	7,053
Investments and other assets		
Other	4,400	4,367
Allowance for doubtful accounts	(192)	(192)
Total investments and other assets	4,208	4,175
Total non-current assets	18,684	18,508
Total assets	31,924	30,171

(Million yen)

	As of May 31, 2025	As of August 31, 2025
Liabilities		
Current liabilities		
Accounts payable - trade	6,647	6,320
Current portion of long-term borrowings	2,639	2,571
Income taxes payable	284	191
Provision for bonuses	46	338
Provision for loss on disaster	50	18
Other	2,320	1,648
Total current liabilities	11,988	11,087
Non-current liabilities		
Long-term borrowings	11,053	10,459
Retirement benefit liability	1,038	1,052
Asset retirement obligations	232	232
Other	693	700
Total non-current liabilities	13,017	12,445
Total liabilities	25,005	23,533
Net assets		
Shareholders' equity		
Share capital	1,961	1,961
Capital surplus	2,186	2,114
Retained earnings	2,938	2,760
Treasury shares	(471)	(471)
Total shareholders' equity	6,614	6,365
Accumulated other comprehensive income		
Remeasurements of defined benefit plans	45	42
Total accumulated other comprehensive income	45	42
Share acquisition rights	208	208
Non-controlling interests	49	20
Total net assets	6,918	6,637
Total liabilities and net assets	31,924	30,171

(2) Quarterly consolidated statements of income and comprehensive income

Quarterly consolidated statement of income

For three-month period

(Million yen)

	Three months ended August 31, 2024	Three months ended August 31, 2025
Net sales	15,231	16,753
Cost of sales	13,093	14,520
Gross profit	2,138	2,232
Selling, general and administrative expenses	2,085	2,080
Operating profit	52	152
Non-operating income		
Interest income	0	3
Dividend income	0	0
Rental income	3	13
Other	9	12
Total non-operating income	13	29
Non-operating expenses		
Interest expenses	30	61
Cost of lease revenue	2	3
Other	8	1
Total non-operating expenses	42	65
Ordinary profit	23	115
Extraordinary income		
Gain on sale of non-current assets	–	15
Subsidy income	–	3
Reversal of provision for loss on store closings	20	–
Total extraordinary income	20	18
Extraordinary losses		
Loss on sale of non-current assets	0	–
Loss on retirement of non-current assets	–	0
Loss on tax purpose reduction entry of non-current assets	–	2
Impairment losses	21	–
Total extraordinary losses	21	2
Profit before income taxes	22	131
Income taxes	156	153
Profit (loss)	(133)	(22)
Profit (loss) attributable to non-controlling interests	(2)	(3)
Profit (loss) attributable to owners of parent	(131)	(18)

Quarterly consolidated statement of comprehensive income

For three-month period

(Million yen)

	Three months ended August 31, 2024	Three months ended August 31, 2025
Profit (loss)	(133)	(22)
Other comprehensive income		
Remeasurements of defined benefit plans, net of tax	(2)	(2)
Total other comprehensive income	(2)	(2)
Comprehensive income	(136)	(24)
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	(133)	(28)
Comprehensive income attributable to non-controlling interests	(2)	3

(3) Notes on quarterly consolidated financial statements

(Note on going concern premise)

Not applicable.

(Notes in the case of significant changes in shareholders' equity)

Not applicable.

(Application of particular accounting treatments concerning preparation of quarterly consolidated financial statements)

(Calculation of tax expense)

Taxes are calculated by multiplying profit before income taxes by a reasonable estimate of the effective tax rate after adjustments for tax-effect accounting for profit before income taxes in the current fiscal year. However, in cases where the calculation of taxes using such estimated effective tax rate yields a result that is not reasonable to a significant extent, the effective statutory tax rate is used.

(Segment information, etc.)

(Segment information)

First three months ended August 31, 2024

1. Reportable segment sales, profit or loss

(Million yen)

	Reportable segments					Other (Note 1)	Total	Adjustments (Note 2)	Amount in quarterly consolidated statement of income (Note 3)
	Dispensing Pharmacy	Drug/ Convenience Store	Storage and Management of Medical Documents	Medical Mall Management	Total				
Net sales									
Sales to external customers	12,419	2,273	154	128	14,975	255	15,231	–	15,231
Inter-segment net sales or transfers	–	–	–	–	–	–	–	–	–
Total	12,419	2,273	154	128	14,975	255	15,231	–	15,231
Segment profit (loss)	84	17	7	31	141	(7)	133	(80)	52

(Notes) 1. The “other” segment includes the temporary help business and the system integration business for pharmaceutical companies.
2. The adjustment to segment profit (loss) of (80) million yen is company expenses not distributed to the reportable segments.
3. Segment profit (loss) is adjusted to be consistent with the operating profit reported in the consolidated statement of income.

2. Information on impairment loss in non-current assets and goodwill by reported segment

(Important impairment loss on non-current assets)

The Dispensing Pharmacy Business posted an impairment loss of 21 million yen.

First three months ended August 31, 2025

1. Reportable segment sales, profit or loss

(Million yen)

	Reportable segments					Other (Note 1)	Total	Adjustments (Note 2)	Amount in quarterly consolidated statement of income (Note 3)
	Dispensing Pharmacy	Drug/ Convenience Store	Storage and Management of Medical Documents	Medical Mall Management	Total				
Net sales									
Sales to external customers	14,151	2,079	157	128	16,517	235	16,753	–	16,753
Inter-segment net sales or transfers	–	–	–	–	–	–	–	–	–
Total	14,151	2,079	157	128	16,517	235	16,753	–	16,753
Segment profit (loss)	235	(4)	15	23	270	(35)	234	(82)	152

(Notes) 1. The “other” segment includes the temporary help business and the system integration business for pharmaceutical companies.
2. The adjustment to segment profit (loss) of (82) million yen is company expenses not distributed to the reportable segments.
3. Segment profit (loss) is adjusted to be consistent with the operating profit reported in the consolidated statement of income.

2. Information on impairment loss in non-current assets and goodwill by reported segment

Not applicable.

(Notes on statement of cash flows)

The Company did not prepare quarterly consolidated statement of cash flows for the first three months of the fiscal year under review. Depreciation (including amortization of intangible assets, excluding amortization of goodwill) and amortization of goodwill for the first three months of the fiscal year under review are as follows.

	First three months ended August 31, 2024	First three months ended August 31, 2025
Depreciation	162 million yen	181 million yen
Amortization of goodwill	182 million yen	195 million yen